Skip to main content

Articles

Page 2 of 9

  1. Patients with relapsed/refractory early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) respond poorly to traditional therapy and have dismal prognosis. CD7 is a promising therapeutic targets fo...

    Authors: Hai-ping Dai, Wei Cui, Qing-ya Cui, Wen-juan Zhu, Hui-min Meng, Min-qing Zhu, Xia-ming Zhu, Lin Yang, De-pei Wu and Xiao-wen Tang
    Citation: Biomarker Research 2022 10:6
  2. Inflammation is a process that protects organs against various potentially harmful stimuli and enables repair. Dysregulated inflammation, however, damages tissues and leads to disease, including cancer. Cancer...

    Authors: Jun Zhang and Nirmal Veeramachaneni
    Citation: Biomarker Research 2022 10:5
  3. The negatively charged aminophospholipid, phosphatidylserine (PtdSer), is located in the inner leaflet of the plasma membrane in normal cells, and may be exposed to the outer leaflet under some immune and bloo...

    Authors: Jiao Wang, Changxin Yu, Junyi Zhuang, Wenxin Qi, Jiawen Jiang, Xuanting Liu, Wanwei Zhao, Yiyang Cao, Hao Wu, Jingxuan Qi and Robert Chunhua Zhao
    Citation: Biomarker Research 2022 10:4
  4. Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially with conventional cytotoxic d...

    Authors: Huajun Zhang, Wuyang Zhang, Longying Jiang and Yongheng Chen
    Citation: Biomarker Research 2022 10:3
  5. Zinc finger proteins are transcription factors with the finger domain, which plays a significant role in gene regulation. As the largest family of transcription factors in the human genome, zinc finger (ZNF) p...

    Authors: Xinxin Li, Mengzhen Han, Hongwei Zhang, Furong Liu, Yonglong Pan, Jinghan Zhu, Zhibin Liao, Xiaoping Chen and Bixiang Zhang
    Citation: Biomarker Research 2022 10:2
  6. The increase in the number of therapeutic alternatives for both newly diagnosed and relapsed/refractory multiple myeloma (RRMM) patients has widened the clinical scenario, leading to a level of complexity that...

    Authors: José-Ángel Hernández-Rivas, Rafael Ríos-Tamayo, Cristina Encinas, Rafael Alonso and Juan-José Lahuerta
    Citation: Biomarker Research 2022 10:1
  7. Relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) has a very poor prognosis with a median overall survival of four to nine months. Achieving a complete molecular response is most often requ...

    Authors: Sophie Voruz, Sabine Blum, Laurence de Leval, Jacqueline Schoumans, Françoise Solly and Olivier Spertini
    Citation: Biomarker Research 2021 9:92
  8. Oral squamous cell carcinoma (OSCC) has poor survival rates. There is a pressing need to develop more precise risk assessment methods to tailor clinical treatment. Epigenome-wide association studies in OSCC ha...

    Authors: Chi T. Viet, Xinyu Zhang, Ke Xu, Gary Yu, Kesava Asam, Carissa M. Thomas, Nicholas F. Callahan, Coleen Doan, Paul C. Walker, Khanh Nguyen, Stephanie C. Kidd, Steve C. Lee, Anupama Grandhi, Clint T. Allen, Simon Young, James C. Melville…
    Citation: Biomarker Research 2021 9:90
  9. Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a rare, distinct subtype of T-ALL characterized by genomic instability, a dismal prognosis and refractoriness to standard chemotherapy. Since it...

    Authors: Francesco Tarantini, Cosimo Cumbo, Luisa Anelli, Antonella Zagaria, Giorgina Specchia, Pellegrino Musto and Francesco Albano
    Citation: Biomarker Research 2021 9:89
  10. Cancer is an intricate disease with inherent intra-tumor heterogeneity at the cellular level because of genetic changes and environmental differences. Cellular heterogeneity exists even within the same tumor t...

    Authors: Ruo Han Huang, Le Xin Wang, Jing He and Wen Gao
    Citation: Biomarker Research 2021 9:88
  11. By the emergence of recombinant DNA technology, many antibody fragments have been developed devoid of undesired properties of natural immunoglobulins. Among them, camelid heavy-chain variable domains (VHHs) an...

    Authors: Yasaman Asaadi, Fatemeh Fazlollahi Jouneghani, Sara Janani and Fatemeh Rahbarizadeh
    Citation: Biomarker Research 2021 9:87
  12. Early cancer diagnosis is a crucial element to improved treatment options and survival. Great research efforts have been made in the search for better performing cancer diagnostic biomarkers. However, the ques...

    Authors: Alien Balian and Frank J. Hernandez
    Citation: Biomarker Research 2021 9:86
  13. Histopathological examination (biopsy) is the “gold standard” for the diagnosis of colorectal cancer (CRC). However, biopsy is an invasive method, and due to the temporal and spatial heterogeneity of the tumor...

    Authors: Miao Jiang, Shuiling Jin, Jinming Han, Tong Li, Jianxiang Shi, Qian Zhong, Wen Li, Wenxue Tang, Qinqin Huang and Hong Zong
    Citation: Biomarker Research 2021 9:85
  14. Identifying and projecting the epidemiological burden of gastric cancer (GC) can optimize the control strategies, especially in high-burden areas.

    Authors: Xiaorong Yang, Tongchao Zhang, Hong Zhang, Shaowei Sang, Hui Chen and Xiuli Zuo
    Citation: Biomarker Research 2021 9:84
  15. Eosinophilia represents a group of diseases with heterogeneous pathobiology and clinical phenotypes. Among the alterations found in primary Eosinophilia, gene fusions involving PDGFRα, PDGFRβ, FGFR1 or JAK2 repre...

    Authors: Simone Romagnoli, Niccolò Bartalucci, Francesca Gesullo, Manjola Balliu, Stefania Bonifacio, Anair Graciela Lema Fernandez, Francesco Mannelli, Davide Bolognini, Elisabetta Pelo, Cristina Mecucci, Paola Guglielmelli and Alessandro Maria Vannucchi
    Citation: Biomarker Research 2021 9:83
  16. Lung cancer is one of the most common cancers in the world. Although medical treatment has made impressive progress in recent years, it is still one of the leading causes of cancer-related deaths in men and wo...

    Authors: Sikai Wu, Chengchu Zhu, Daolin Tang, Q. Ping Dou, Jianfei Shen and Xin Chen
    Citation: Biomarker Research 2021 9:82
  17. The identification of biomarkers to select patients with metastatic renal cell carcinoma (mRCC) most likely to respond to combination immunotherapy (IO) is needed. We sought to investigate an association of th...

    Authors: Matthew D. Tucker, Landon C. Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman, Emily N. Kinsey, Kristin K. Ancell, Kathryn E. Beckermann, Nancy B. Davis, Renee McAlister, Kerry Schaffer, Andrew J. Armstrong, Michael R. Harrison, Daniel J. George, W. Kimryn Rathmell, Brian I. Rini…
    Citation: Biomarker Research 2021 9:80
  18. Immune checkpoint inhibitors (ICIs) have heralded the advent of a new era in oncology by holding the promise of prolonged survival in severe and otherwise treatment-refractory advanced cancers. However, the re...

    Authors: Xiaoyan Liu, Yuequan Shi, Dongming Zhang, Qing Zhou, Jia Liu, Minjiang Chen, Yan Xu, Jing Zhao, Wei Zhong and Mengzhao Wang
    Citation: Biomarker Research 2021 9:79
  19. The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of ...

    Authors: Takahiro Einama, Yoji Yamagishi, Yasuhiro Takihata, Takafumi Suzuki, Tamio Yamasaki, Yuichi Hirose, Kazuki Kobayashi, Naoto Yonamine, Ibuki Fujinuma, Takazumi Tsunenari, Makiko Koga, Yusuke Ishibashi, Ken Nagata, Takehiro Shiraishi, Akiko Nakazawa, Toshimitsu Iwasaki…
    Citation: Biomarker Research 2021 9:78
  20. Myeloid-derived suppressor cells (MDSC) are a group of immature cells that produced by emergency myelopoiesis. Emerging evidences have identified the vital role of MDSC in cancer microenvironment, in which MDS...

    Authors: Zhaonian Hao, Ruyuan Li, Yuanyuan Wang, Shuangying Li, Zhenya Hong and Zhiqiang Han
    Citation: Biomarker Research 2021 9:77

    The Correction to this article has been published in Biomarker Research 2022 10:7

  21. The ten-eleven translocation 1 (TET1) protein is a 5-methylcytosine hydroxylase that belongs to the TET protein family of human α-ketoglutarate oxygenases. TET1 recognizes and binds to regions of high genomic ...

    Authors: Wenzheng Liu, Guanhua Wu, Fei Xiong and Yongjun Chen
    Citation: Biomarker Research 2021 9:76
  22. Multiple myeloma (MM) is a treatable plasma cell cancer with no cure. Clinical evidence shows that the status of minimal residual disease (MRD) after treatment is an independent prognostic factor of MM. MRD in...

    Authors: Hong Ding, Juan Xu, Zhimei Lin, Jingcao Huang, Fangfang Wang, Yan Yang, Yushan Cui, Hongmei Luo, Yuhan Gao, Xinyu Zhai, Weicui Pang, Li Zhang and Yuhuan Zheng
    Citation: Biomarker Research 2021 9:75
  23. Earlier studies have shown that lymphomatous effusions in patients with diffuse large B-cell lymphoma (DLBCL) are associated with a very poor prognosis, even worse than for non-effusion-associated patients wit...

    Authors: Sina Abdollahi, Seyedeh Zahra Dehghanian, Liang-Yi Hung, Shiang-Jie Yang, Dao-Peng Chen, L. Jeffrey Medeiros, Jung-Hsien Chiang and Kung-Chao Chang
    Citation: Biomarker Research 2021 9:74
  24. The role of PLAC8 in tumorigenesis has been gradually elucidated with the development of research. Although there are common molecular mechanisms that enforce cell growth, the impact of PLAC8 is varied and can, i...

    Authors: Misha Mao, Yifan Cheng, Jingjing Yang, Yongxia Chen, Ling Xu, Xun Zhang, Zhaoqing Li, Cong Chen, Siwei Ju, Jichun Zhou and Linbo Wang
    Citation: Biomarker Research 2021 9:73
  25. Tumor-associated macrophages (TAMs), at the core of immunosuppressive cells and cytokines networks, play a crucial role in tumor immune evasion. Increasing evidences suggest that potential mechanisms of macrop...

    Authors: Yingqi Qiu, Tong Chen, Rong Hu, Ruiyi Zhu, Chujun Li, Yingchen Ruan, Xiaoling Xie and Yuhua Li
    Citation: Biomarker Research 2021 9:72
  26. Biological therapy is considered an alternative treatment capable of eliciting the same effects on tumors as surgery, radiotherapy, and chemotherapy. As a major player in biological therapy, oncolytic viruses ...

    Authors: Shengye Jin, Qin Wang, Hao Wu, Da Pang and Shouping Xu
    Citation: Biomarker Research 2021 9:71
  27. The use of blood biomarkers after mild traumatic brain injury (mTBI) has been widely studied. We have identified eight unresolved issues related to the use of five commonly investigated blood biomarkers: neuro...

    Authors: Daniel B. Hier, Tayo Obafemi-Ajayi, Matthew S. Thimgan, Gayla R. Olbricht, Sima Azizi, Blaine Allen, Bassam A. Hadi and Donald C. Wunsch II
    Citation: Biomarker Research 2021 9:70
  28. Lack of biomarkers and in vitro models has contributed to inadequate understanding of the mechanisms underlying the inferior clinical response to immune checkpoint inhibitors (ICIs) in patients with oncogene-d...

    Authors: Weijie Ma, Jie Zeng, Shuai Chen, Yue Lyu, Kyra A. Toomey, Chinh T. Phan, Ken Y. Yoneda and Tianhong Li
    Citation: Biomarker Research 2021 9:69
  29. Wnt signaling was initially recognized to be vital for tissue development and homeostasis maintenance. Further studies revealed that this pathway is also important for tumorigenesis and progression. Abnormal e...

    Authors: Zhuo Wang, Tingting Zhao, Shihui Zhang, Junkai Wang, Yunyun Chen, Hongzhou Zhao, Yaxin Yang, Songlin Shi, Qiang Chen and Kuancan Liu
    Citation: Biomarker Research 2021 9:68
  30. Extracellular vesicles are membrane vesicles that are released into the extracellular environment and accumulate in the circulation in vascular disease. We aimed to quantify circulating extracellular vesicles ...

    Authors: Akram Abolbaghaei, Marc-André Langlois, Helen R Murphy, Denice S. Feig and Dylan Burger
    Citation: Biomarker Research 2021 9:67
  31. Deubiquitinases (DUBs) are enzymes that control the stability, interactions or localization of most cellular proteins by removing their ubiquitin modification. In recent years, some DUBs, such as USP7, USP9X a...

    Authors: Hu Lei, Jiaqi Wang, Jiacheng Hu, Qian Zhu and Yingli Wu
    Citation: Biomarker Research 2021 9:66
  32. MicroRNAs may be important regulators of risk for type 2 diabetes. The purpose of this longitudinal observational study was to assess whether circulating microRNAs predicted improvements in fasting blood gluco...

    Authors: Elena Flowers, Isabel Elaine Allen, Alka M. Kanaya and Bradley E. Aouizerat
    Citation: Biomarker Research 2021 9:65
  33. Cell therapy has evolved rapidly in the past several years with more than 250 clinical trials ongoing around the world. While more indications of cellular therapy with chimeric antigen receptor – engineered T ...

    Authors: Hongtao Liu, Chongxian Pan, Wenru Song, Delong Liu, Zihai Li and Lei Zheng
    Citation: Biomarker Research 2021 9:62
  34. Neoantigens, a type of tumor-specific antigens derived from non-synonymous mutations, have recently been characterized as attractive targets for cancer immunotherapy. Owing to the development of next-generatio...

    Authors: Xuan Zhao, Xiaoxin Pan, Yi Wang and Yi Zhang
    Citation: Biomarker Research 2021 9:61
  35. Tumor angiogenesis induces local hypoxia and recruits immunosuppressive cells, whereas hypoxia subsequently promotes tumor angiogenesis. Immunotherapy efficacy depends on the accumulation and activity of tumor...

    Authors: Wuzhen Chen, Lesang Shen, Jingxin Jiang, Leyi Zhang, Zhigang Zhang, Jun Pan, Chao Ni and Zhigang Chen
    Citation: Biomarker Research 2021 9:59
  36. In Western countries, ovarian cancer (OC) still represents the leading cause of gynecological cancer-related deaths, despite the remarkable gains in therapeutical options. Novel biomarkers of early diagnosis, ...

    Authors: E. Krasniqi, A. Sacconi, D. Marinelli, L. Pizzuti, M. Mazzotta, D. Sergi, E. Capomolla, S. Donzelli, M. Carosi, A. Bagnato, T. Gamucci, S. Tomao, C. Natoli, P. Marchetti, A. Grassadonia, N. Tinari…
    Citation: Biomarker Research 2021 9:57
  37. Contemporary to the rapidly evolving landscape of cancer immunotherapy is the equally changing understanding of immune tumor microenvironments (TMEs) which is crucial to the success of these therapies. Their r...

    Authors: Sarabjot Pabla, R. J. Seager, Erik Van Roey, Shuang Gao, Carrie Hoefer, Mary K. Nesline, Paul DePietro, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Lenzo, Margot Schoenborn, Shengle Zhang, Roger Klein, Sean T. Glenn…
    Citation: Biomarker Research 2021 9:56
  38. Every year around the world, more than 2 million women are diagnosed with breast cancer and genital tract cancers. However, there are rare studies comprehensively describing the global and regional trends of i...

    Authors: Ming Yi, Tianye Li, Mengke Niu, Suxia Luo, Qian Chu and Kongming Wu
    Citation: Biomarker Research 2021 9:55
  39. Long non-coding RNAs (lncRNAs) represent a diverse class of RNAs involved in the regulation of various physiological and pathological cellular processes, including transcription, intracellular trafficking, and...

    Authors: Francesca Maria Orlandella, Giovanni Smaldone, Giuliana Salvatore, Luigi Vitagliano, Alessandra Cianflone, Rosanna Parasole, Giuliana Beneduce, Giuseppe Menna, Marco Salvatore and Peppino Mirabelli
    Citation: Biomarker Research 2021 9:54
  40. Myelodysplastic syndrome with myelofibrosis (MDS-MF) has been associated with an inferior prognosis compared with MDS without MF. However, MDS-MF is not listed independently as a subtype of MDS, and its clinic...

    Authors: Minghua Hong, Junqing Wu, Lifeng Ma, Xiaoping Han, Ting Lu, Zhaoming Wang, Jing Zhao, Lizhen Liu, Huarui Fu, Weijia Huang, Weiyan Zheng, Jingsong He, Guoqing Wei, Huanping Wang, Zhimei Chen, He Huang…
    Citation: Biomarker Research 2021 9:53
  41. After decades during which the treatment of acute myeloblastic leukemia was limited to variations around a skeleton of cytarabine/anthracycline, targeted therapies appeared. These therapies, first based on mon...

    Authors: Lamia Madaci, Julien Colle, Geoffroy Venton, Laure Farnault, Béatrice Loriod and Régis Costello
    Citation: Biomarker Research 2021 9:50

Annual Journal Metrics